Today's Portrait Highlights

Lanthio Pharma

Lanthio Pharma is focused on discovering and developing lantipeptide drugs for serious diseases. We are working on lanthipeptides as new treatment for fibrosis, stroke, heart failure and multiple sclerosis. To discover and produce drug candidates, we apply our proprietary LanthioPep technology. This technology uses modified Lactococcus bacteria to make constrained peptides, called lanthipeptides. Our lanthipeptides are more disease target selective and more stable in plasma compared to linear wild-type peptides, making them more suitable as drug candidates.

Daisygrip: Reducing time, costs and risks of infection

Daisygrip is the first hygienically reusable venous tourniquet and has a unique intuitive locking system. The simpler application and disinfection method ensure lasting safety and permanently reduce costs. With daisygrip, every routine blood sample is taken time-efficiently and under hygienic conditions, without changing current treatment procedures.

Aspekta

Aspekta is a full service PR consultancy in Sweden and Denmark. We provide analysis, strategy and activities in public relations and communications. We are based in Malmö, Copenhagen and Stockholm. With the help of partners and networks, we can solve our clients’ problems in all the Nordic countries and the EU. Aspekta is a member of PRECIS, the Swedish Public Relations consultancies’ trade association (www.precis.se), and its counterpart in Denmark, Public Relations Branchen (www.publicrelationsbranchen.dk). Aspekta complies with industry standards.